Key result
Molecular modeling and mutagenesis revealed a generalized extracellular binding pocket for IKs activators formed by KCNE1 and KCNQ1 subunits, explaining the mechanism of enhanced IKs currents.
Why the study?
Certain chemical activators of the cardiac I Ks channel are only active in the presence of the accessory KCNE1 subunit, but the mechanism underlying this phenomenon was unclear.
The identification of a specific extracellular binding pocket for IKs activators on the KCNQ1/KCNE1 complex provides a structural map for designing future therapies for arrhythmia syndromes caused by IKs loss-of-function.
KCNE1-dependent IKs activators require caution for translation; leaves open development of independent compounds for LQTS therapy.
The cardiac I Ks ion channel comprises KCNQ1, calmodulin, and KCNE1 in a dodecameric complex which provides a repolarizing current reserve at higher heart rates and protects from arrhythmia syndromes that cause fainting and sudden death. Pharmacological activators of I Ks are therefore of interest both scientifically and therapeutically for treatment of I Ks loss-of-function disorders. One group of chemical activators are only active in the presence of the accessory KCNE1 subunit and here we investigate this phenomenon using molecular modeling techniques and mutagenesis scanning in mammalian cells. A generalized activator binding pocket is formed extracellularly by KCNE1, the domain-swapped S1 helices of one KCNQ1 subunit and the pore/turret region made up of two other KCNQ1 subunits. A few residues, including K41, A44 and Y46 in KCNE1, W323 in the KCNQ1 pore, and Y148 in the KCNQ1 S1 domain, appear critical for the binding of structurally diverse molecules, but in addition, molecular modeling studies suggest that induced fit by structurally different molecules underlies the generalized nature of the binding pocket. Activation of I Ks is enhanced by stabilization of the KCNQ1-S1/KCNE1/pore complex, which ultimately slows deactivation of the current, and promotes outward current summation at higher pulse rates. Our results provide a mechanistic explanation of enhanced I Ks currents by these activator compounds and provide a map for future design of more potent therapeutically useful molecules.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2023) studied IKs loss-of-function disorders. Small molecule IKs activators was evaluated on Binding pocket characterization and IKs activation mechanism. Molecular modeling and mutagenesis revealed a generalized extracellular binding pocket for IKs activators formed by KCNE1 and KCNQ1 subunits, explaining the mechanism of enhanced IKs currents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: